EKSO
Ekso Bionics Holdings, Inc. NASDAQ Listed Jan 17, 2014$23.33
+13.20%
vs $20.61
Mkt Cap $56.6M
52w Low $2.82
100.0% of range
52w High $23.33
50d MA $12.26
200d MA $7.59
P/E (TTM)
-4.8x
EV/EBITDA
—
P/B
6.3x
Debt/Equity
0.3x
ROE
-750.7%
P/FCF
-4.7x
RSI (14)
87.30
ATR (14)
$1.97
Beta
0.78
50d MA
$12.26
200d MA
$7.59
Avg Volume
152.0K
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
1414 Harbour Way South · San Rafael, CA 94804 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | AMC | -0.03 | -2.04 | -6700.0% | 11.21 | -0.1% | +2.1% | +5.0% | -1.8% | -1.2% | +1.3% | — |
| Feb 23, 2026 | AMC | -0.08 | -1.56 | -1850.0% | 10.64 | +0.0% | -4.4% | -5.2% | +3.9% | +1.2% | +0.9% | — |
| Oct 28, 2025 | AMC | -0.99 | -0.54 | +45.5% | 4.81 | -0.2% | +9.1% | -2.9% | +5.7% | -4.3% | -0.6% | — |
| Jul 28, 2025 | AMC | -1.20 | -1.24 | -3.3% | 4.53 | -19.2% | -27.4% | +10.3% | -4.1% | +0.3% | -5.7% | — |
| May 5, 2025 | AMC | -1.65 | -1.80 | -9.1% | 7.15 | -14.8% | -9.1% | +1.2% | -5.8% | +3.2% | +0.8% | — |
| Mar 3, 2025 | AMC | -0.07 | -0.14 | -100.0% | 7.23 | -2.5% | -1.2% | -8.0% | -8.1% | -4.1% | -9.3% | — |
| Oct 28, 2024 | AMC | -0.08 | -0.10 | -25.0% | 16.95 | -20.1% | -15.0% | -2.9% | -8.2% | +3.7% | -1.8% | — |
| Jul 29, 2024 | AMC | -0.11 | -0.13 | -18.2% | 22.35 | -16.8% | -28.9% | -0.9% | +0.0% | -4.8% | -2.0% | — |
| Apr 29, 2024 | AMC | -0.16 | -0.20 | -25.0% | 19.35 | +0.8% | -3.9% | +2.4% | +1.6% | +1.6% | +3.1% | — |
| Mar 4, 2024 | AMC | -0.11 | -0.22 | -100.0% | 31.50 | -16.2% | -24.8% | -5.1% | +5.3% | -2.5% | -9.1% | — |
| Oct 26, 2023 | AMC | -0.31 | -0.24 | +22.6% | 11.25 | +0.0% | +6.5% | +22.5% | +11.5% | +19.3% | -4.6% | — |
| Jul 27, 2023 | AMC | -0.28 | -0.31 | -10.7% | 17.85 | +0.0% | -0.8% | -1.7% | -4.3% | +6.3% | -5.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $10.58 | $9.56 | -9.6% | -18.3% | -9.3% | +9.1% | +11.5% | -7.5% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.16 | +0.0% | +0.5% | -3.6% | -4.0% | +5.4% | +3.4% |
| Jul 29 | Lake Street | Maintains | Buy → Buy | — | $4.53 | $3.66 | -19.2% | -27.4% | +10.3% | -4.1% | +0.3% | -5.7% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.15 | $6.09 | -14.8% | -9.1% | +1.2% | -5.8% | +3.2% | +0.8% |
| Mar 4 | Lake Street | Maintains | Buy → Buy | — | $7.23 | $7.05 | -2.5% | -1.2% | -8.0% | -8.1% | -4.1% | -9.3% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.23 | $7.05 | -2.5% | -1.2% | -8.0% | -8.1% | -4.1% | -9.3% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.68 | $11.04 | +3.4% | -2.5% | -6.3% | +6.3% | -5.7% | -2.8% |
| Oct 29 | Lake Street | Maintains | Buy → Buy | — | $16.95 | $13.55 | -20.1% | -15.0% | -2.9% | -8.2% | +3.7% | -1.8% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.95 | $13.55 | -20.1% | -15.0% | -2.9% | -8.2% | +3.7% | -1.8% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.35 | $18.60 | -16.8% | -28.9% | -0.9% | +0.0% | -4.8% | -2.0% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.35 | $19.50 | +0.8% | -3.9% | +2.4% | +1.6% | +1.6% | +3.1% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.50 | $26.40 | -16.2% | -24.8% | -5.1% | +5.3% | -2.5% | -9.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.50 | $33.30 | +5.7% | +12.9% | +5.5% | -5.2% | -5.1% | -1.3% |
| Jul 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.95 | $26.40 | +1.7% | +1.7% | -0.6% | +4.6% | -0.5% | +4.4% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $86.70 | $87.00 | +0.3% | -0.9% | -0.2% | +0.2% | -3.8% | +2.9% |
| Nov 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $86.70 | $87.00 | +0.3% | -0.9% | -0.2% | +0.2% | -3.8% | +2.9% |
| Nov 25 | Aegis Capital | Maintains | Buy → Buy | — | $86.70 | $87.00 | +0.3% | -0.9% | -0.2% | +0.2% | -3.8% | +2.9% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.70 | $63.00 | +0.5% | -2.6% | -0.5% | +2.7% | +0.2% | +0.5% |
| Aug 3 | Aegis Capital | Maintains | Buy → Buy | — | $97.80 | $96.60 | -1.2% | -0.5% | -2.3% | +0.8% | +0.6% | -2.6% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.50 | $149.85 | +36.8% | +20.1% | -18.9% | +18.1% | -13.9% | +1.7% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.40 | $51.75 | -3.1% | +6.2% | -2.6% | -4.6% | -2.6% | +0.0% |
| May 21 | Aegis Capital | Maintains | Buy → Buy | — | $48.60 | $44.85 | -7.7% | -6.2% | +7.2% | +17.8% | -6.0% | -2.2% |
| Apr 13 | Aegis Capital | Maintains | Buy → Buy | — | $41.70 | $40.65 | -2.5% | +14.0% | +13.6% | -6.1% | -3.0% | +4.6% |
| Mar 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $49.50 | $48.00 | -3.0% | -14.2% | -10.2% | +47.6% | -19.2% | -6.6% |
No insider trades available.
8-K · 1.01
! Medium
Ekso Bionics Holdings, Inc. -- 8-K 1.01: Equity Issuance
Ekso Bionics secured $15.75 million in equity funding from APLD Intermediate HoldCo LLC, providing capital for operations and growth initiatives.
May 4
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
EKSO's equity incentive plan diluting existing shareholders by ~5.25% signals management confidence in growth, but investors should monitor whether operational performance justifies this significant ownership stake reduction.
Apr 16
8-K · 1.01
! Medium
Ekso Bionics Holdings, Inc. -- 8-K 1.01: Equity Issuance
Ekso Bionics completed an equity exchange with APLD Intermediate HoldCo LLC, potentially diluting existing shareholders while bringing in new capital or strategic backing.
Feb 17
Institutional (13F) — Top 17
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Hood River Capital Management Llc | 133,636 | $9M | New | Mar 2026 |
| 2 | Dba Trading, Llc | 270,432 | $3M | Added | Mar 2026 |
| 3 | Mink Brook Asset Management Llc | 95,331 | $1M | New | Mar 2026 |
| 4 | Feynman Point Asset Management Llc | 39,900 | $425K | New | Mar 2026 |
| 5 | Dauntless Investment Group, Llc | 35,493 | $378K | New | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 34,032 | $362K | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 31,813 | $339K | New | Mar 2026 |
| 8 | Sei Investments Co | 25,603 | $273K | New | Mar 2026 |
| 9 | Cresset Asset Management, Llc | 17,964 | $92K | — | Sep 2025 |
| 10 | Roble, Belko & Company, Inc | 2,338 | $25K | Added | Mar 2026 |
| 11 | Compagnie Lombard Odier Scma | 1,666 | $18K | — | Mar 2026 |
| 12 | Ubs Group Ag | 1,024 | $11K | Added | Mar 2026 |
| 13 | Royal Bank Of Canada | 295 | $3K | New | Mar 2026 |
| 14 | Cwm, Llc | 7 | $75 | New | Mar 2026 |
| 15 | Morgan Stanley | 6 | $52 | — | Dec 2025 |
| 16 | Redwood Park Advisors Llc | 2 | $22 | — | Mar 2026 |
| 17 | Steward Partners Investment Advisory, Llc | 1 | $11 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 19,463 | $197K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 8,540 | $87K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 4,318 | $44K | Feb 2026 |
| 4 | U.S. CORE EQUITY 2 PORTFOLIO | 1,808 | $16K | Jan 2026 |
| 5 | Dimensional U.S. Core Equity 2 ETF | 106 | $922 | Jan 2026 |
Valuation
Market Cap
$56.6M
Enterprise Value
$56.4M
P/E (TTM)
-4.75x
Forward P/E
—
PEG Ratio
-0.00x
P/B
6.27x
P/S
4.42x
P/FCF
-4.72x
EV/EBITDA
—
Shares Out
2.4M
Financials (TTM)
Revenue
$12.8M
Net Income
-$11.7M
EBITDA
-$9.8M
Free Cash Flow
-$12.0M
Op Cash Flow
-$11.8M
EPS Basic
$-4.91
EPS Diluted
$-4.91
EPS Forward
$-0.10
Gross Margin
53.5%
Op Margin
-104.1%
Net Margin
-91.4%
Balance Sheet
Total Assets
$20.1M
Total Liab.
$11.1M
Total Equity
$9.0M
Cash
$1.2M
LT Debt
$945K
Book Value/Sh
$3.72
Debt/Equity
0.29x
Current Ratio
1.63
Quick Ratio
1.07
Returns & Growth
ROE
-750.7%
ROA
-79.8%
ROIC
-101.2%
Rev Growth YoY
-28.6%
EPS Growth YoY
-776.8%
Price Returns
2W
—
1M
-1.7%
3M
+16.4%
6M
+149.5%
12M
+160.5%
Technicals
52W High
$23.33
52W Low
$2.82
50d MA
$12.26
200d MA
$7.59
RSI (14)
87.30
ATR (14)
$1.97
Beta
0.78
Avg Volume
152K
Dividends
Div Rate
$0.09
Div Yield
0.8%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 25, 2026 6:47am
· Source: financialmodelingprep.com